Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous s stock reports and market updates.
Activision Blizzard, Inc. (NASDAQ: ATVI) shares gained 1.21 percent to close at $20.85 a share Thursday. The stock traded between $20.53 and $21.50 on volume of 16.10 million shares traded. Analysts at Bank of America Merrill Lynch have recently upgraded the company’s rating to “buy” from “neutral”. Shares of Activision Blizzard have gained approximately 16.0 percent year-to-date.
Find out more about Activision Blizzard including full access to the free equity report at:
AstraZeneca plc (NYSE: AZN) shares declined 2.10 percent to close at $65.27 a share Thursday. The stock traded between $65.08 and $66.87 on volume of 2.10 million shares traded. Analysts at JPMorgan have recently downgraded the company’s rating to “underweight” from “neutral”. Shares of AstraZeneca have gained approximately 10.0 percent year-to-date.
Find out more about AstraZeneca including full access to the free equity report at:
Emulex Corporation (NYSE: ELX) shares gained 0.28 percent to close at $7.18 a share Thursday. The stock traded between $7.14 and $7.49 on volume of 1.33 million shares traded. Analysts at DA Davidson have recently initiated coverage on the company with a “buy” rating and a price target of $10.00. Shares of Emulex have gained approximately 0.30 percent year-to-date.
Find out more about Emulex including full access to the free equity report at:
Steelcase Inc. (NYSE: SCS) shares declined 4.81 percent to close at $14.06 a share Thursday. The stock traded between $13.98 and $14.43 on volume of 903,661 shares traded. Analysts at Longbow Research have recently downgraded the company’s rating to “neutral” from “buy”. Shares of Steelcase have fallen approximately 11.0 percent year-to-date.
Find out more about Steelcase including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing